Lantern Pharma Inc.
LTRN
$1.77
$0.000.00%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 9.46% | 8.42% | 6.13% | 15.00% | 10.05% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -24.56% | -21.87% | -19.08% | -7.20% | 4.91% |
| Operating Income | 24.56% | 21.87% | 19.08% | 7.20% | -4.91% |
| Income Before Tax | 3.10% | 19.95% | 17.62% | 0.90% | -8.46% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 3.10% | 19.95% | 17.62% | 0.90% | -8.46% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 3.10% | 19.95% | 17.62% | 0.90% | -8.46% |
| EBIT | 24.56% | 21.87% | 19.08% | 7.20% | -4.91% |
| EBITDA | 24.57% | 21.88% | 19.09% | 7.21% | -4.91% |
| EPS Basic | 9.56% | 21.59% | 18.60% | 1.59% | -8.02% |
| Normalized Basic EPS | 9.62% | 21.68% | 18.35% | 2.00% | -7.56% |
| EPS Diluted | 9.56% | 21.59% | 18.60% | 1.59% | -8.02% |
| Normalized Diluted EPS | 9.62% | 21.68% | 18.35% | 2.00% | -7.56% |
| Average Basic Shares Outstanding | 6.05% | 2.32% | 1.33% | 0.66% | 0.28% |
| Average Diluted Shares Outstanding | 6.05% | 2.32% | 1.33% | 0.66% | 0.28% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |